Cullinan Oncology LLC (NASDAQ:CGEM) — Market Cap & Net Worth
Market Cap & Net Worth: Cullinan Oncology LLC (CGEM)
Cullinan Oncology LLC (NASDAQ:CGEM) has a market capitalization of $894.21 Million ($894.21 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9404 globally and #2617 in its home market, demonstrating a -4.89% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cullinan Oncology LLC's stock price $20.63 by its total outstanding shares 61458046 (61.46 Million). Also see total assets of Cullinan Oncology LLC for a full breakdown of the balance sheet.
Cullinan Oncology LLC Market Cap History: 2021 to 2026
Cullinan Oncology LLC's market capitalization history from 2021 to 2026. Data shows change from $948.30 Million to $1.27 Billion (-6.32% CAGR). Also see how efficiently does Cullinan Oncology LLC generate cash for how efficiently the company converts equity into cash flow.
Index Memberships
Cullinan Oncology LLC is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.03% | #266 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #988 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.05% | #156 of 263 |
Weight: Cullinan Oncology LLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cullinan Oncology LLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cullinan Oncology LLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Cullinan Oncology LLC (CGEM) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
50.06x
Cullinan Oncology LLC's market cap is 50.06 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $948.30 Million | $18.94 Million | -$65.04 Million | 50.06x | N/A |
Competitor Companies of CGEM by Market Capitalization
Companies near Cullinan Oncology LLC in the global market cap rankings as of September 18, 2026. Review CGEM goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Cullinan Oncology LLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Cullinan Oncology LLC Historical Marketcap From 2021 to 2026
Between 2021 and today, Cullinan Oncology LLC's market cap moved from $948.30 Million to $ 1.27 Billion, with a yearly change of -6.32%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.27 Billion | +99.32% |
| 2025 | $636.09 Million | -15.02% |
| 2024 | $748.56 Million | +19.53% |
| 2023 | $626.26 Million | -3.41% |
| 2022 | $648.38 Million | -31.63% |
| 2021 | $948.30 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Cullinan Oncology LLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $894.21 Million USD |
| MoneyControl | $894.21 Million USD |
| MarketWatch | $894.21 Million USD |
| marketcap.company | $894.21 Million USD |
| Reuters | $894.21 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cullinan Oncology LLC
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049,… Read more